These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 12885836)
1. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO; J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836 [TBL] [Abstract][Full Text] [Related]
2. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M; Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916 [TBL] [Abstract][Full Text] [Related]
3. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I; J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827 [TBL] [Abstract][Full Text] [Related]
4. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348 [TBL] [Abstract][Full Text] [Related]
5. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ; Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167 [TBL] [Abstract][Full Text] [Related]
6. [Improved treatment results in children with AML: Results of study AML-BFM 93]. Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M; Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551 [TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
8. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120 [TBL] [Abstract][Full Text] [Related]
9. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia. Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663 [TBL] [Abstract][Full Text] [Related]
11. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777 [TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review. Gamis AS Pediatr Blood Cancer; 2005 Jan; 44(1):13-20. PubMed ID: 15534881 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268 [TBL] [Abstract][Full Text] [Related]
14. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356 [TBL] [Abstract][Full Text] [Related]
15. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group. Barnard DR; Alonzo TA; Gerbing RB; Lange B; Woods WG; Pediatr Blood Cancer; 2007 Jul; 49(1):17-22. PubMed ID: 16856158 [TBL] [Abstract][Full Text] [Related]
16. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. Aladjidi N; Auvrignon A; Leblanc T; Perel Y; Bénard A; Bordigoni P; Gandemer V; Thuret I; Dalle JH; Piguet C; Pautard B; Baruchel A; Leverger G; J Clin Oncol; 2003 Dec; 21(23):4377-85. PubMed ID: 14645428 [TBL] [Abstract][Full Text] [Related]
17. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565 [TBL] [Abstract][Full Text] [Related]
18. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Abildgaard L; Ellebaek E; Gustafsson G; Abrahamsson J; Hovi L; Jonmundsson G; Zeller B; Hasle H Ann Hematol; 2006 May; 85(5):275-80. PubMed ID: 16518605 [TBL] [Abstract][Full Text] [Related]
19. [Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group]. Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G Klin Padiatr; 1992; 204(4):236-45. PubMed ID: 1518259 [TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA; J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]